Molecular focus in p63 and correlated human diseases by Hashemi, Mehrdad et al.










 , Mohammad hassan Shamei
2
 
  1  Department of Genetics,Islamic azad university, Tehran medical branch,Tehran,Iran  
  2 Department of Genetics,Islamic azad university, Science and  research branch, Tehran,Iran   
 
*Corresponding Author: email address: mhashemi@iautmu.ac.ir (M. Hashemi) 
 
ABSTRACT 
     The p63 gene, a member of the p53 gene family, is expressed into at least six protein isoforms.The 
transcription factor p63 is a homologue of the tumor suppressor p53. Unlike p53, which is dispensable for 
normal development, p63 is critical for the development of stratified epithelial tissues such as epidermis, 
breast, and prostate. p63, , is transcribed from two different promoters giving rise to two different proteins: 
p63, a member of the p53 family, is transcribed from two different promoters giving rise to two different 
proteins: TAp63 that contains the N-terminal transactivation domain and ΔN that lacks this domain. p63 
encodes multiple protein isoforms with both transactivating and transcriptional repressor activities that can 
regulate a wide spectrum of target genes. p63 is also implicated in tumor formation and progression in 
stratified epithelia, with evidence for both tumor suppressive and oncogenic properties. 
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p63 gene and protein structure 
     The  human p63 gene resides on chromosome 
3q27–29, and consists of 15 exons spread over 
about 220 kB, with introns up to 100 kB in length 
(Fig. 1C). p63 can be expressed from two 
different promoters, one immediately preceding 
the first exon and a second lying in the third 
intron. Transcription from the first and second 
promoters gives rise to TA- or ΔN- aminotermini 
of p63, respectively. Both TA- and ΔN- 
transcripts can be alternatively spiced at the 
carboxy-terminus, leading to α,β, and γ isoforms 
of TA- and ΔNp63. All p63 proteins encode a 
DNA-binding domain, which is approximately 
60% identical at the amino acid level to the DNA-
binding domain of p53, and an oligomerization  
domain with about 37% identity to that of p53 
(Figs. 1A, B). TA isoforms possess an N-terminal 
acidic transactivation domain with low homology 
to the transactivation domain of p53 (about 22% 
identity), while ΔNp63 proteins lack this domain. 
The different C-termini of α, β, and γ isoforms 
also contribute to the diversity of p63 proteins; α, 
but not β and γ, isoforms contain a Sterile alpha-
motif (SAM) domain that functions as a protein–
protein interaction module in other proteins [6,7], 
(Fig. 1B). The complexity of p63 transcript and 
protein expression foretells functional complexity 
of this gene at the biochemical and biological 
levels. 
Early experiments revealed that TAp63 isoforms 
could transactivate a reporter gene through a 
canonical p53 responsive DNA binding site, as 
well as induce cell death [2,3]. In contrast, ΔNp63 
proteins can act in a dominantnegative manner 
toward p53-mediated transcriptional activation[2]. 
The DNA binding domains of p53 and p63 are 
highly homologous; all the amino acid residues in 
the p53 DNA binding domain that directly contact 
DNA or coordicoordinate a zinc ion necessary for 
DNA binding activity are 100% conserved in the 
p63 DNA binding domain. This implies not only 
sequence conservation, but also conservation of 
the structure of these protein domains. NMR 
studies of the p53 and p63 DNA binding domains 
have confirmed a highly similar global fold and 
essentially identical secondary structure elements 
for these protein domains [8]. Consistent with the 
sequence and structural homology of the p53 and 
p63 DNA binding domains, p63 proteins can bind 
to p53 consensus DNA binding sites in vitro and 
in vivo [9,10]. Other names for this gene include 
KET, p51, p40 and p73L [4]. 




 p63 exhibit high amino acid identity with p53, 
especially among their transactivation (TA) 
domains, DNA-binding domain (DBD), and 
tetramerization (ISO) domain (fig. 1). Unlike 
TP53, TP63 encode a number of isoforms (fig. 1). 
For TP63, two transcription initiation sites were 
initially described one that would give rise to 
proteins containing the TA domain (the TA 
isotypes) and another that would give rise to 
proteins lacking this domain (the DNisotypes).For 
TP63, additional transcripts were subsequently 
uncovered in human and rodents, resulting from 
both the use of at least four transcription initiation 
sites and extensive alternative splicing at the 5_ 
end of the gene. Additionally,extensive alternative 
splicing is seen at the 3_ end of the gene, resulting 
in three different C-termini for p63. For TP63, 
differential splicing of intron 8 creates additional 
variability in the final polypeptide sequences 
(either GTKRP or A), but the functional 
significance of this is not known. The extended 3_ 
coding sequences of the a isotypes of TP63 
encode a protein-protein–interaction motif that 
resembles the sterile-a-motif (SAM) domain 
which is not contained in p53. SAM domains are 
small globular protein-protein–interaction 
modules that are usually involved in homo- and 
heterooligomerization with other SAM domains. 
It has been demonstrated that the p63  SAM 
domains do not oligomerize with one another and 





   
 
 
























Fig. 1 – Functional domains of p53 and p63 proteins. (A) Functional domains of p53. p53 is composed of three primary 
domains: an N-terminal transactivation domain (TA), a central DNA binding domain, and a C-terminal oligomerization 
domain (Oligo). (B)Functional domains of p63 proteins. Percentages represent p53-identical residues found in p63. In 
addition, p63 has additional C-terminal domains called the sterile alpha motif (SAM) domain and transactivation 
inhibitory domain (TID). (C) Gene structure of  p63.  Both promoters and the #N and α, β, γ splicing events are shown.   
 
Differential Properties of the p63 Isotypes   
     The p63 gene, is expressed into at least six 
protein isoforms which are divided into two 
groups, those containing the transcription 
activation domain (TA isoforms) and those that 
do not (N_isoforms). The TA isoforms are similar 
to p53 in that they are able to activate 
transcription of specific target genes and induce 
cell cycle arrest and apoptosis.  
Apoptosis is referred to as programmed cell death. 
The mechanisms controlling apoptosis remain 
largely obscure. 
While there is considerable variation in the 
signals and requisite cellular metabolic events 




necessary to induce apoptosis in diverse cell 
types, the morphological features associated with 
apoptosis are highly conserved [107,108]. 
Increase of cytosol calcium can affect the 
potential for mitochondrion membrane 
permeability and leaking cytochrom C and induce 
apoptosis[109,110] 
 The _N isoforms are unable to activate 
transcription, and act in adominant negative 
manner, inhibiting transcription activation by both 
p53 and TA isoformsThe functional significance 
of p63 in regulating cell proliferation in various 
stratified epithelial cells has previously been 
proposed.To investigate how these isoforms are 
used in ocular surface epithelia, the spatial 
distribution of p63 isoforms within human ocular 
surface epithelia.Regarding the C-terminal region, 
an α-isoform specific region was detected in all 
layers of the conjunctiva and limbus, as well as in 
the basal to intermediate layers of the cornea. β-
isoform specific regionwas detected in the basal 
to intermediate layers of the limbus. γ-isoform 
specific region was detected in almost all layers of 
all epithelia.Among the six p63 isoforms, only 
ΔNp63a was detected in the basal to intermediate 
layers of the limbus and conjunctiva. These 
resultssuggest that ΔNp63a is the most dominant 
isoform within human ocular surface epithelia. 
This isoform may contribute, at least in part, to 
themaintenance of cell proliferative capacity 
within the ocular surface epith. 
From the primary sequence, one would predict 
that only the p63 isotypes, which contain the 
acidic TA domain, have transactivation activity, 
whereas the ΔN isotypes, which lack this domain, 
do not have transactivation activity.Although this 
is generally true, there are still some exceptions to 
this rule. The largest p63 isotype, TAp63a , is 
unable to drive transcription on the optimized 
p53-responsive element PG13, in contrast to TA-
p63b and TA-p63g. (fig. 1). This unexpected lack 
of activity is caused by an inhibitory effect that is 
contained within the a-specific C-terminal end. 
This inhibitory activity of the a tail also acts in 
trans toward TA-p63b/g transcriptional 
activation, indicating that the various p63 isotypes 
can have opposing properties. The repressive 
activity has been mapped to the region, 
downstream from the SAM domain, that has been 
denoted as the ―transactivation inhibitory domain‖ 
(TID). Tentative evidence suggests the presence 
of other regions within p63 that either promote or 
repress transactivation activity. Interestingly, 
activation of transcription can be mediated by p63 
domains other than the canonical TA domain[11].  
In addition, there is accumulating evidence that 
TAp63 isoforms can be transcriptionally active at 
levels below the limit of detection by Western 
blot [14,36]. For this reason, the participation of 
TAp63 isoforms in the overall function of the p63 
gene cannot be ruled out. However, we can 
unequivocally conclude that ΔNp63α plays a 
critical role in the biological function of the p63 
gene. For this reason, the biochemical activity of 
the ΔNp63α protein merits further attention[1].  
 
Expression patterns of p63 in adult tissues 
     p63 is expressed in a confined manner, with 
the highest expression found in the basal cells of 
various epithelial tissues and the ΔNp63α 
transcripts being the most abundant. 
Expression patterns of p63 provide insight to its 
biological role.p63 is immunolocalized in the 
basal layers of stratified epithelial tissues. These 
include stratified squamous tissues,such as the 
epidermis, oral mucosa, and cervical 
epithelium;transitional epithelium, found in the 
mucosa of the urinary bladder; and complex 
glands, including the prostate and mammary, 
salivary, and lacrimal glands [2,40,41]. Generally, 
p63 protein expression is restricted to the basal 
layers of these epithelial structures, which lie 
directly on the basement membrane. This basal 
compartment of stratified epithelia is often 
considered to harbor cells of high proliferative 
capacity,which replenish the terminally 
differentiated populations in the more luminal 
strata [26]. p63 is also highly expressed in cancers 
derived from these tissues, including squamous 
cell carcinomas of the head and neck [40]. The 
lack of stratified epithelia in p63 −/− mice, 
combined with its normal expression in basal 
epithelia cells and squamous cancer cells, led to 
the hypothesis that p63 is required for the 
maintenance or differentiation of progenitor cell 
populations necessary for epithelial 
development[1].  
 
Transcriptional regulation of p63 expression   




     The highly restricted expression patterns of 
p63 in normal and malignant tissues imply 
conditional and coordinated regulation of p63 
expression. Despite increasing knowledge about 
the biological function of p63 in the tissues in 
which it is expressed, relatively little is known 
about the mechanisms governing transcription of 
the p63 gene. ΔNp63α plays a role in maintaining 
the viability and proliferative capacity of basal 
epithelial cells, therefore ΔNp63α expression may 
be controlled in part by upstream signals involved 
in the survival or proliferative capacity of these 
cells. One study has implicated EGFR signaling in 
regulation of ΔNp63α expression [47].p63 plays a 
critical role in embryonic development, and 
understanding its transcriptional regulation during 
this period can expose signaling pathways in 
which p63 is involved.ΔNp63α expression is 
directly induced by bone morphogenetic proteins 
(BMPs) during zebrafish development through 
binding sites for Smad4 and Smad5 in the ΔNp63 
promoter [16].BMPs are growth factors which act 
as important determinants of cell fate and tissue 
lineage [51]. ΔNp63α transcript levels decline in 
both epidermal tissue and mammary cell lines 
after treatment with DNA damaging agents such 
as UV radiation, cisplatin, or adriamycin[28,52]. 
Interestingly, this may be mediated by the 
recruitment of ΔNp63α protein to a binding site in 
its own promoter following DNA damage, 
thereby repressing its own transcription [52]. UV-
B-induced DNA damage decreases levels of DN-
p63a (a naturally occurring dominant-negative 
form of the protein),before increasing levels of 
p53. Simultaneously, the levels of the 
transactivating TA-p63 isoforms increase. The 
down-regulation of dominant-negative DN-p63a, 
as well as the up-regulation that activates TA-p63 
isoforms, may be a prerequisite for UV-induced 
apoptosis in skin This notion is supported by the 
recent observation that the transactivating TA-
p63a  isoforms are required for p53-dependent 
apoptosis induced by DNA damage. The role that 
this switch from inhibitory to activating p63 
isoforms plays in normal skin development[11]. 
 
 Regulation of p63 protein—stability and post-
translational modifications  
     Like p53, ΔNp63α exists as a phosphoprotein 
[9], and phosphorylation of ΔNp63α increases 
following DNA damage or other cell stresses 
[43,54]. Coincident with this stress induced 
phosphorylation is an increase in the ubiqitination 
and proteosomal degradation of the ΔNp63α 
protein [43]. It has been hypothesized that the 
inverse regulation of p53 and ΔNp63α protein 
stability represent a mechanism allowing rapid 
modulation of coordinately regulated target genes 
destabilizing a repressor while stabilizing a 
transactivator through simultaneously executed 
similar mechanisms. In contrast to ΔNp63α, 
ectopically expressed TAp63 proteins can 
accumulate in response to genotoxic stress, but no 
evidence of endogenous TAp63 regulation by this 
mechanism has been reported [55,56]. p63 
proteins can also be sumoylated, potentially 
affecting stability and transcriptional activity 
[57,58]. Interestingly, the stability of p63 proteins 
appears to be inversely correlated with their 
transactivation ability. TAp63γ, which is the most 
active transactivator of the p63 isoforms, is often 
undetectable by Western blot, even in amounts 
that have robust transcriptional activity [36]. 
TAp63α, with lower transactivation potential,is 
more easily detected, but deletion of the C-
terminal TID from TAp63α increases its 
transcriptional activity and reduces protein 
expression levels [36]. it is possible that p63 
stability are controlled through a similar 
mechanism of negative feedback. However, it is 
clear that Mdm2 itself is not a factor in p63 
degradation [55,64–66]. Continued study of p63 
post-translational modification and protein 
stability will provide insight to common and 
distinct mechanisms of regulation of the p53 
family.All the aforementioned instances of 
regulation of ΔNp63α expression upregulation by 
activation of the pro-survival PI3K pathway, and 
downregulation by genotoxic stress and cell 
differentiation are consistent with the proposed 
function of p63 as a transcription factor that acts 
to maintain the viability and proliferative capacity 
of basal epithelial cells. However,these findings 
are also consistent with p63 being merely a 
marker for the viability and proliferative capacity 
of these cells.Additional information is necessary 
to confer functional importance namely, target 
genes modulated by p63[1].  
 
DNA binding specificity of p63  




    The DNA binding domain of p63 retains 
significant homology to that of p53, and p63 
proteins can bind to p53 consensus DNA binding 
sites in vitro and in vivo [9,10,70]. However, the 
divergent biological roles of these two genes 
imply that they regulate distinctsubsets of target 
genes. This paradox can be partially explained by 
the existence of a distinct p63 consensus DNA 
binding site, to which p63 proteins will bind 
preferentially.   
 
Identification of p63 target genes  
     A new target gene Scotin induced byTAp63 
during epithelial differentiation. This gene was 
previously isolated as a p53-inducible 
proapoptotic gene and the protein is located in the 
endoplasmic reticulum and in the nuclear 
membrane. Scotin expression is induced in 
response to endoplasmic reticulum (ER) stress in 
a p53 dependent or independent manner. We 
detected Scotin upregulation in primary 
keratinocyte cell lines committed to differentiate. 
Scotin also is expressed in the supra basal layer of 
the epidermis in parallel with TAp63, but not 
ΔNp63 expression. We conclude that Scotin is a 
new p63 target gene induced during epithelial 
differentiation, a complex process that also 
involves ER stress induction[12]. 
Similar, but distinctive DNA-binding specificities 
implies distinct but overlapping subsets of target 
genes for p53 and p63 (Fig. 2). This idea is 
supported by the genes identified as targets of 
direct p63 regulation. p63 can regulate 
transcription of the well-characterized p53 target 
genes p21, 14-3-3σ, and GADD45α [5,9,35]. p21 
is an inhibitor of cyclin-dependent kinases (cdks) 
that arrests cell cycle progression [71]; 14-3-3σ 
similarly inhibits cell proliferation by 
sequestering the proteins (cyclin B1 and cdc2) 
that initiate mitosis [72]. p53 induces expression 
of these genes following DNA damage, thereby 
preventing further cell proliferation [73,74]. p21- 
and 14-3-3σ- mediated growth arrest is important 
not only in the response to genotoxic stress, but 
also in cell cycle withdrawal characteristic of 
terminally differentiating cells [75–77]. ΔNp63α 
binds to p53-responsive elements in the promoters 
of both p21 and 14-3-3σ in vitro and in vivo [9]. 
Interestingly, ΔNp63α binds to one of the 14-3-3σ 
sites with higher affinity than p53; this site 
displays divergence from the perfect p53 
consensus sequence, and supports the hypothesis 
that p63 can bind to certain DNA sequences 
preferentially compared to p53 [9].ΔNp63α 
represses transcription through these binding 
sites,and loss of ΔNp63α expression during 
keratinocyte differentiation corresponds with 
increased transcription of p21 and 14-3-3σ, and 
cell cycle withdrawal [9]. This implies a model of 
coordinate regulation of p21 and 14-3-3σ by 
ΔNp63α and p53, in which ΔNp63α represses 
transcription of these genes, and either loss of 
ΔNp63α-mediated repression during 
differentiation or transactivation by p53 following 
cell stress will result in upregulation of p21 and 
14-3-3σ expression. Another example of a gene 
coordinately regulated by p53 and p63 is REDD1, 
a mediator of reactive oxygen species (ROS) and 
oxygen stress sensitivity. REDD1 is upregulated 
by p53 following cell stress; however, REDD1 
expression colocalizes with p63 expression during 
development, and is virtually absent in p63 −/− 
mice [78].  
 
 




Figure 2.  p53 and p63 regulate overlapping but distinct subsets of target genes. Diagram showing a proposed model 
for the relationship between p53 and p63 target genes. Genes reported to fall into each category of regulation are listed 
below[1].    
 
Few genes have been identified as exclusive p63 
target genes.The gene Jagged1 (JAG1) is directly 
regulated by p63 proteins but not p53 [81]. JAG1 
encodes a ligand for Notch receptors;Notch 
signaling is critical for cell fate determination, and 
influences limb and craniofacial development, 
suggesting that p63 regulation of Notch signaling 
may play a role during embryogenesis [82,83]. 
Pigment epithelium derived factor (PEDF) is 
another gene recently identified as a target of p63, 
but not p53 [84]. Other genes that play a role in 
epidermal development and differentiation have 
been observed to be regulated by p63, such as the 
keratinocyte differentiation markers loricrin and 
involucrin [30]; however, whether these are direct 
target genes has not been established. In addition, 
a microarray screen has identified a large number 
of potentially p63-regulated genes using 
ectopically overexpressed p63 proteins in a non-
epithelial cell line [85]. An approach to identify 
genes regulated by endogenous p63 in squamous 
cells will likely provide insight to transcriptional 
programs regulated by p63 under physiologically 
relevant conditions.   
 
Target genes—p53 regulated, p63 regulated, or 
both?   
     The physiological role and functional 
significance of the target gene may be the most 
important consideration in defining it as a p53 or 
p63 target gene. For instance, PERP was 
originally identified as a p53 target gene [79]; 
however, the recent report that PERP is regulated 
by p63 and plays an important role in 
maintenance of epithelial integrity suggests that it 
should be functionally considered a p63 target 
gene [80]. It has also been shown that IGFBP-3 is 
a direct target gene of p63, and is negatively 
regulated by ΔNp63α in vivo [29]. IGFBP-3 was 
previously reported to be a p53 target gene; 
however, the relevance of IGFBP-3 in p53-
mediated cell death is tenuous. These data suggest 
that regulation of IGFBP-3 by p63 may be more 
physiologically relevant[1].  
 
 
Role of p63 in tumor suppressor  
     One study suggests that p63 +/− mice show an 
increased susceptibility to tumor formation, and 
that tumors forming in these mice often display 
loss of heterozygosity (LOH) for the remaining 
wild-type p63 allele [86]. Despite these data, a 
number of observations contradict the idea that 
p63 acts as a tumor suppressor in humans. p53 is 
the most commonly mutated gene in human 
cancer, supporting its role as a crucial tumor 
suppressor; in contrast, the p63 gene is very rarely 
mutated in human tumors or cancer cell lines 
[3,87]. In addition, LOH at chromosome 17p13, 
where p53 resides, is a common event during 
tumorigenesis that allows the elimination of a 
wild-type p53 allele [88–91]. No LOH occurs at 
the p63 locus in cancer; in fact, the 3q27–29 
region containing the p63 gene is amplified in a 
number of human malignancies [92,93]. 
The most compelling evidence refuting a tumor 
suppressive role for p63 came with establishment 
of p63 −/− mice. p53 −/− mice are 
developmentally normal but highly susceptible to 
the rapid development of spontaneous tumors 
[94]. Mice deficient in other tumor suppressors, 
such as p16INK4A and p19ARF, similarly 
develop tumors at an early age [95]. In contrast, 
p63 −/− mice display gross developmental 
abnormalities. The most striking of these is a 
complete lack of all stratified squamous epithelia 
and their derivatives, including epidermis, 
mammary glands, prostate, and other tissues 
[11,12]. These data place the primary biological 
role of p63 outside the realm of tumor suppression 
governed by its more famous sibling, p53.  
 
Role of p63 in apoptosis 
      Several studies have suggested that p63 is 
involved in apoptotic signaling, but its role this 
process remains controversial. Necrosis and 
apoptosis are two main separated  
pathways for cell death. Apoptosis is a planned 
and genetically controlled cell death. 
Expression of genes inducing apoptosis like BAX 
which are important for formation of membrane 
channels of mitochondrion and cytochrom C 




leakage and in long periods, presence of active 
Protein,  BAX is more prominent [111]. 
pathway loss due to over aggregation of glycogen 
in muscle cells and make apoptosis by 
phosphorylation of P65 and gene expression of 
NF.KB of muscle cell[112].Influenza virus by 
activating endogenous pathways of apoptosis 
through the expression of Excessive protein BAX 
and BCL inhibit the formation of channels and 
mitochondrial cytochrome c and output can be 
caused to induce apoptosis[114,113]. 
 But role of cytokines are remarkable Search 
activity in the virus infected cells and 
commissioning process with the presence of 
inflammatory cytokines such as TNF-α can route 
FAS / FASL-induced apoptosis is caused [115-
117]. 
The TA isoforms of p63 can bind to p53-
consensus and induce p53-target genes.The 
TAp63_ isoform is the weakest transcription 
activator because of the presence of an inhibitory 
domain in its C-terminus[13]. 
 TAp63 protein can induce apoptosis similar to 
p53, and both death receptor and mitochondrial 
apoptotic pathways have been implicated in this 
process [100]. In contrast, ΔNp63α appears to 
oppose apoptosis. Forced expression of ΔNp63α 
in mouse epidermis results in a reduction in UV-
induced apoptosis [28], and disruption of ΔNp63α 
expression in squamous carcinoma cells increases 
sensitivity to apoptosis inducing agents [29]. In 
addition,ΔNp63α expression can be regulated by 
the PI3K pathway, a potent inhibitor of apoptosis 
[48]. Finally, ΔNp63α negatively regulates 
transcription of a pro-apoptotic gene, IGFBP-3 
[29]. The role of other p63 isotypes in apoptosis is 
unclear.One study employing p63 −/− MEFs as a 
model system concluded that p63 was necessary 
for p53-mediated apoptosis [10]. In contrast, it 
was recently reported that p63 is completely 
dispensable for p53-dependent apoptosis in T 
cells [101]. The precise role of p63 proteins in 
apoptosis, the DNA-damage response, and 
modulation of p53 signaling will be elucidated 




Fig. 3. The p63 isoforms can have opposing functions but a balance of these is required for normal development. The 
TA isoforms of p63, which may act as tumour suppressors, activate the transcription of genes ultimately leading to cell 
cycle arrest or apoptosis. The _N isoforms act in a dominant negative fashion, counteracting the effects of p53 and the 
TA isoforms, thus allowing for proliferation of stem cells. The regulation of these isoforms is critical for development 
of epithelial structures. 
 
Role of p63 in human cancers  
     p63 is rarely mutated in human cancers. The 
majority of tumors maintain p63 expression, and 
in many cases p63 appears to be over expressed or 
the p63 locus is amplified, consistent with p63 
performing a pro-proliferative or oncogenic role. 
A potential role for p63 in tumorigenesis is 
supported by the finding that p63 is a target of 




genomic amplification and/or over expression in 
>80% of primary head and neck squamous cell 
carcinomas (HNSCC) as well as other squamous 
epithelial malignancies (Table 1). A genome-wide 
micro-array screen of non-small cell lung cancer 
revealed that the 3q26-29 locus encompassing p63 
is frequently amplified in squamous cell 
carcinomas of the lung, suggesting that over 
expression of p63 facilitates tumorigenesis A 
study of 245  
esophageal tumors demonstrated that both Tap63 
and _Np63 isoforms are specifically upregulated 
at the transcript level in squamous cell carcinoma, 
and _Np63 was the predominant isoform 
expressed at the protein level \ Some tumor types 
have been reported to lose p63 expression, 
suggesting that p63 loss accelerates 
tumorigenesis. This is supported by in vitro data 
which reveal that disruption of p63 in squamous 
cell lines resulted in upregulation of genes 
associated with increased capacity for invasion 
and metastasis in tumors .(Table 1) gives an 









Role of p63 in Mammalian Embryonic 
Development  
     Immunohistochemical analyses of mouse 
embryos show high p63 levels in epithelial cells, 
especially in progenitor or stem-cell populations 
of epithelial tissues. The main isotype in these 
cells is the dominant-negative ΔN-p63a isotype, 
which likely acts in the maintenance of the 
proliferative capacity of such cells. As these cells 
start to differentiate, their ΔN-p63a levels 
gradually drop, and the levels of TA-p63 
increase[15]. It thus appears that dominant-
negative ΔN-p63a is crucial for the maintenance 
of the capacity of regenerative proliferation of 
epithelial stem cells. Indeed, application of 
retinoic acid, which prevents degradation of ΔN-
p63a, effectively blocks the differentiation of skin 
epithelial stem cells in culture.In mouse embryos, 
TP63 expression is first evident in nuclei of cells 
in the basal layer, which develop into the 
progenitor cells of the epidermis and related 
derivatives,such as hair and sweat glands. Basal 




cells of the cervix,tongue, esophagus, mammary 
glands, prostate, and urothelium also show high 
levels of p63. Early TP63 expression is further 
evident in ectodermal cells of  the limb buds and 
tail bud, branchial arches, and the oral epithelium. 
In the developing limb bud, TP63 expression is 
restricted to the apical ectodermal ridge (AER),a 
key determinant of limb-bud emergence and 
progression.Proper signaling along the antero-
posterior axis between the AER and the 
underlying mesoderm is crucial for normal 
formation of the distal limb. 
The sites of TP63 expression are well in line with 
the phenotypic consequences of homozygous 
TP63 inactivation in mice. These p63-deficient 
newborns exhibit striking limb defects. The 
forelimbs are severely truncated, and the 
hindlimbs are lacking altogether. The skin of the 
knockout animals is absent, and newborn animals 
die from dehydration shortly after birth. Other 
skin derivatives,such as hair shafts and follicles 
are not present.Finally, p63-deficient animals lack 
tooth primordia and eyelids. Both the maxilla and 
the mandible are truncated,and the secondary 
palate fails to close. Taken together, the defects in 
p63-deficient mice present as severe ectodermal 
dysplasia, abnormal limb development,and facial 
dysmorphism[11]. 
 
Upstream and Downstream from p63: Smad 
and Jagged  
     Although one may speculate that p63 is 
involved in epidermal differentiation through 
loricrin and involucrin. The first and only bona 
fide target genes for p63 are Jagged1 (JAG1) and 
Jagged2 (JAG2), which encode ligands for Notch 
receptors.A cDNA microarray analysis showed an 
increased JAG1 and JAG2 expression in cell lines 
that were transfected with adenoviral vectors 
expressing TA-p63g. The physiological 
significance of this result was convincingly 
demonstrated by chromatin-immunoprecipitation 
experiments,which revealed binding of TA-p63g 
to promoter elements of JAG1 in vivo. Also, co-
culturing of Notch1 expressing Jurkat cells with 
p63-transfected cells led to an up-regulation of 
HES-1, a downstream target of Notch signaling. 
This indicates that p63 can trigger the Notch 
pathway in neighboring cells, possibly by 
induction of JAG1 and JAG2. Although JAG1 
mutations cause Alagille syndrome in humans, no 
human disease has been linked to JAG2 
mutations. Interestingly, mice with homozygous 
inactivating Jag2 mutations have syndactyly and 
defective craniofacial development, including 
cleft palate (CP) (Sidow et al. 1997; Jiang et al. 
1998). Much work still needs to be done to 
elucidate other in vivo targets of p63 
transactivation and to determine the downstream 
effects of this transactivation[11].  
 
TP 63 and disease : EEC-like Family  
Syndromes  
     In 1999, linkage mapping of human EEC-like 
syndromes identified a locus on 3q27, coinciding 
with the localization of TP63. At the same time, 
these results established that germline mutations 
in p63 are not associated with a cancer-prone 
phenotype, as is the case for p53/Li-Fraumeni 
syndrome. Moreover, the implication of p63 in 
EEC syndrome paved the way to testing of the 
TP63 gene in the EEC-like syndromes, and by 
that, provided insight into the molecular 
mechanisms underlying this group of disorders 
(table 2).A group of multiple-congenital-anomaly 
syndromes is characterized by EEC. The 
prototypic EEC syndrome has this triad of 
features. EEC syndrome frequently presents with 
other associated anomalies, such as lacrimal-tract 
anomalies, urogenital anomalies, anal atresia, and 
conductive hearing loss. EEC syndrome is 
relatively common, with 1200 cases having been 
reported in the literature, and is well known for 
having both variable expressivity and reduced 
penetrance. A comparison of interfamilial and 
intrafamilial variability in expressivity found 
significantly greater interfamilial variability, 
suggesting that more than one gene or allele might 
be involved. 




Several autosomal dominant syndromes have 
been described that share features with EEC 
including lacrimo-auricular-dental-digital 
(LADD) syndrome (MIM149730) and LMS. 
Bamshad et al. (2000) proposed the combination 
of the aforementioned four syndromes as ―LEAD 
syndrome‖ (named for limb, lacrimal, ectodermal, 
and apocrine dysplasia). Other dominant 
syndromes resemble the EEC syndrome in only 
one or two of the cardinal features; for example, 
AEC syndrome(also known as ―Hay-Wells 
syndrome‖) and Rapp-Hodgkin syndrome (RHS 
[MIM 129400]) lack ectrodactyly,the 
ectrodactyly–cleft palate (ECP) syndrome(MIM 




129830) lacks ectodermal dysplasia, ADULT 
syndrome and the ectrodactyly–ectodermal 
dysplasia (EE) syndrome (MIM 129810) lack 
cleft lip with or without cleft palate (CL/P), and 
isolated SHFM is characterized only by 
ectrodactyly[11].  We can see the highest rate of 
mutation in exson7 then exon6 and exon8 in 
table2. 
 
Fig. 4. Comparison of p63 phenotypes in humans and mice. Representative phenotypes of Human syndromes involving p63 
mutations, including (a) ectrodactyly, (b) ectodermal dysplasia including absence of hair and eyebrows, and skin infections, (c) cleft 
lip and palate and lacrimal ductobstruction, and  (d) mammary gland hypoplasia and absence of nipples
EEC Syndrome   
     To date, 20 different heterozygous p63 
mutations in 53 families with EEC syndrome are 
known (reported by Celli et al. [1999], Ianakiev et 
al. [2000], Wessagowit et al.[2000], Kosaki et al. 
[2001], and van Bokhoven et al.[2001]. All except 
one of the mutations in families with EEC 
syndrome give rise to amino acid substitutions in 
the DBD that is common to all known p63 
isoforms. The arginine codons 204, 227, 279, 280, 




and 304 were mutated in several unrelated 
patients. These amino acids are crucially 
important for direct interactions with DNA target 
sequences, and their mutation is highly 
detrimental to DNA binding and transactivation 
activity. One explanation is the high mutability of 
the corresponding codons. Indeed, 46 of the 51 
mutations in families with EEC syndrome are CrT 
transitions at CpG sites. Hence, the high 
mutability of 5-methylcytosine at CpG sites is a 
likely explanation for the high proportion of 
recurrent mutations in EEC syndrome. These data 
established that missense mutations in EEC 
syndrome disrupt DNA binding for all p63 
isotypes. The effects on transactivation will differ, 
however,depending on the sum of the 
transactivating TAp63g and the dominant-
negative ΔN-p63a activities, thereby making it 
difficult to predict the net result on transactivation 
in vivo. A single frameshift mutation found in a 
patient with EEC syndrome did not disrupt the 
DNA-binding capacity. Strikingly, this frameshift 
mutation, which affects the p63a isotypes only, 
conferred a gain of transactivation on the 
otherwise repressive ΔN-p63a isotype . 
 
AEC (Hay-Wells) Syndrome   
     AEC syndrome, which is also known as ―Hay-
Wells syndrome,‖has little or no limb 
involvement but instead includes 
ankyloblepharon, which is a partial or complete 
fusion of the eyelids that is very rare in other 
EEC-like syndromes (Hay and Wells 1976). Also, 
the ectodermal dysplasia is much more 
pronounced in AEC than in the other EEC-like 
syndromes. Severe infections of the scalp are 
common during the first years of life. Mutations 
in 12 unrelated patients with AEC have been 
detected, and 10 of these mutations are missense 
mutations within the SAM domain of p63 . These 
mutations are predicted to disrupt protein-protein 
interactions,by either destroying the compact 
globular structure of the SAM domain or 
substituting amino acids that are crucial for such 
interactions (McGrath et al.2001). Tentative 
evidence indicates that the effects of the SAM-
domain mutations varies for different isotypes and 
at different DNA target sites (L. Guerrini, 
personal communication).For the functional and 
developmental consequences of these mutations 
to be better understood, it will be necessary to 
identify the protein(s) interacting with the SAM 
domain[11].   
 
ADULT Syndrome   
     ADULT syndrome differs from EEC syndrome 
by the absence of facial clefting in patients with 
the former (Propping and Zerres 1993). Instead, 
these patients show neurodermitic signs—namely, 
exfoliative dermatitis of the digits—and excessive 
freckling. Another missense mutation was 
reported in an isolated patient with features of 
ADULT syndrome. This mutation lies in exon 3_ 
and results in a substitution (N6H) that is specific 
to the DN-p63 isotypes[11].   
 
LMS   
     Phenotypically, LMS is most similar to 
ADULT syndrome (Propping et al.2000). Three 
different mutations have been detected in patients 
with LMS. Two isolated patients with an LMS 
phenotype have, in exons 13 and 14, frameshift 
mutations that result in truncations of the p63a 
protein.Therefore, the abundant p63 product in 
epithelial cells would be missing the TID. The 
third mutation was identified in the large Dutch 
family with LMS. The mutation is in exon 4 and 
creates a substitution (
G76W) just upstream from the TA domain (P. 
Duijf, personal communication).  
 
SHFM  
     SHFM is genetically heterogeneous, and three 
loci have previously been identified by linkage 
analysis and study of SHFM1, on 7q21-q22; 
SHFM2 (MIM 313350), on Xq26; and SHFM3 
(MIM 600095), on 10q24. A subsequent analysis 
of a group of ∼50 unrelated patients with SHFM 
revealed five mutations, suggesting that p63 
mutations account for ∼10% of these cases (van 
Bokhoven et al. 2001). Five of the seven p63 
mutations seen in patients with SHFM are unique 
to this syndrome—namely, missense mutations 
K193E and K194E, nonsense mutations Q634X 
and E639X, and splice-site mutation IVS4-2ArC 
(which causes the insertion of a proline residue at 
position 233). The two aforementioned nonsense 
mutations create truncations of eight and three 
amino acids, respectively, in the Cterminal end of 
the a isotypes. This C-terminal domain contains 




the repressive domain, and removal of the last 
eight amino acids partially abolishes this 
repression (V.Doetsch, personal communication). 
In addition, the lastfive amino acids, KEEGE, 
may form an endoplasmic retention signal, 
suggesting that protein routing may also be 
impaired. Two other mutations, both at the same 
codon, have been found in both SHFM and EEC 
syndrome—namely, R280C and R280H. This 
arginine,like the lysines at positions 193 and 194, 
is not in direct contact with the DNA, and 
mutation of these residues probably induces more-
subtle effects on the DNA-binding capacity of 
p63[11].   
 
Genotype-Phenotype Correlations: Molecular 
Dissection of the p63 Gene  
      The pattern of mutations in the five human 
disorders linked to p63 reveals a remarkable 
specificity of the molecular defects in this gene 
and clinical consequences.The clustering of 
mutations in the DBD, for EEC syndrome,and in 
the SAM domain, for AEC syndrome establishes 
a clear genotype-phenotype correlation. 
Furthermore,the mutations in ADULT syndrome, 
as well as most of the mutations in LMS and 
SHFM, are distinctive to these syndromes. 
Interestingly, within families, mutation of the 
arginine at position 280 always has the same 
phenotypic outcome namely, either SHFM or 
EEC syndrome supporting the notion that genetic 
modifiers or epigenetic factors have a modulatory 
effect.Evidence for genetic modifiers is found in 
mice with mutations in genes that are likely to be 
involved in p63 pathways. The limb phenotype of 
the dactylaplasia (Dac) mouse, a model for 
human SHFM3, not only requires mutation of the 
dactylin gene but also requires homozygosity for 
an as-yet-unknown modifier allele that has been 
denoted as ―mDac‖ .Another fascinating example, 
in the syndactylism (sm) mouse, is caused by a 
disruption of the p63 target gene Jag2. The sm 
phenotype is strongly modified by genetic 
background, and several loci, acting as either 
enhancers or suppressors, have been mappe.One 
of these, the suppressor locus on mouse 
chromosome 16,is syntenic to human 
chromosome 3q27-q29 and encompasses the 
TP63 gene. TP63 may be a modifier of the mutant 
JAG2 phenotype, and, by analogy, JAG2 may be a 
modifier of the mutant p63 phenotype. The 
hypothesis that there are specific modifier genes 
can be further pursued by molecular studies of 
large families with a single TP63 mutation. Other 
candidate modifiers include (a) genes that are 
known to be mutated in human syndromes with 
features that overlap those of the EEC syndrome 
or (b) genes that are active in genetic programs 
that are governed by p63. For full comprehension 
of the normal and disrupted properties of the 
complex array of p63 isotypes, it will be 
necessary to identify those genes that act together 
with or in response to p63. It is to be expected that 
some of these will be found either to be modifiers 
of the spectrum of EEClike disorders or to 
underlie LADD syndrome or the 90% of cases of 
SHFM that lack TP63 mutations[11].  
 
Evolution of  P63 gene  
    The p63 gene is extraordinarily conserved, 
even among distantly related species. For 
instance, p63 proteins shown 99% amino acid 
identity between human and mouse orthologs, and 
93% amino acid identity between human and 
Xenopus laevis [2,105]. This implies an 
evolutionarily ancient function for p63. The N-
terminal domain is the least conserved of the three 
domains among the family members (30% 
identity between p73 and p53, 22% identity 
between p63 and p53 and 30% identity between 
p63 and p73).Phylogenetic analysis of the p53 
family members has suggested that the ancestor 
gene of the p53 family is most like p63, and that 
p53 is a more recent evolutionary adaptation 
[106]. This is an attractive hypothesis, because of 
the nature of the most prevalent genotoxic insult 
to which early organisms would have been 
exposed ultraviolet radiation and the tissue that 
bears the brunt of such exposure the skin. Thus, 
one can imagine a scenario by which UV 
radiation promoted the 
evolution of a tumor suppressor (p53) from a 
transcription factor that already functioned to 
handle decisions of cell fate (p63), and was 
specifically expressed in the relevant tissue. This 
evolutionary hypothesis is complicated by the fact 
that TAp63 isoforms have not been identified in 
zebrafish or Xenopus model systems at this time; 




only ΔNp63 transcripts and proteins are detected. 
This leads to several possibilities: 
1)TAp63 isoforms are evolutionarily ancient and 
physiological important players in the overall 
function of the p63 gene, but simply have not yet 
been identified in zebrafish and Xenopus. 
2)TAp63 isoforms are dispensable for overall 
function of the p63 gene. 
3)The most ancient p63 precursor gene did not 
possess a transactivation domain, and TAp63 
isoforms are actually later evolutionary additions 
that appear in mammalian species, and permit the 
formation of a more complex and heavily 
stratified epidermis than that found in fish and 
amphibians.This last possibility is supported by 
the fact that in the p63 gene, the TA promoter and 
start site lies 120–160 kB upstream from the ΔN 
start site and DNA binding domain in both mice 
and humans. In contrast, the p53 transactivation 
domain and DNA binding domain lie within 4 kB 
of genomic sequence, suggesting that the addition 
of the TA domain to the p63 gene is a relatively 
recent event[1].   
 
Electronic-Database Information  
     Accession numbers and URLs for data 
presented herein are as follows: 
IARC TP53 Mutation Database, 
http://www.iarc.fr/p53/ (for mutation frequencies 
in the TP53 gene) Online Mendelian Inheritance 
in Man (OMIM), 
http://www.ncbi.nlm.nih.gov/Omim/ (for EEC 
syndrome [MIM 604292], LADD syndrome 
[MIM 149730],ADULT syndrome [MIM 
103285], LMS [MIM 603543],AEC syndrome 
[MIM 106260], RHS [MIM 129400], ECP 
syndrome [MIM 129830], EE syndrome [MIM 
129810],SHFM1 [MIM 183600], SHFM2 [MIM 
313350], SHFM3[MIM 600095], and SHFM4 
[MIM 605289]).  
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